Home > Oncology > WCLC 2022 > WCLC 2022 Congress Round-Up > KEYNOTE-604: Very durable responses on pembrolizumab plus EP in SCLC

KEYNOTE-604: Very durable responses on pembrolizumab plus EP in SCLC

Presented By
Dr Charles Rudin, Memorial Sloan Kettering Cancer Center, NY, USA
Conference
WCLC 2022
Trial
Phase 3, KEYNOTE-604
Doi
https://doi.org/10.55788/59d29021
Long-term follow-up data of the phase 3 KEYNOTE-604 trial displayed an ongoing clinically meaningful improvement in overall survival (OS) and progression-free survival (PFS) in patients with extensive-stage small cell lung cancer (ES-SCLC) if they received pembrolizumab plus etoposide/platinum (EP) chemotherapy instead of EP alone [1]. The KEYNOTE-604 trial (NCT03066778) compared the efficacy and safety of pembrolizumab plus EP with placebo plus EP in the first-line treatment of patients with ES-SCLC (n=453). A significant PFS benefit of the experimental therapy over the control therapy was reported in the published results of the primary analysis (HR 0.75; P=0.0023) [2]. Dr Charles Rudin (Memorial Sloan Kettering Cancer Center, NY, USA) presented the updated results with 3.5 years of additional follow-up. After a median follow-up of 43.3 months, the median ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on